Decreased testosterone recovery after androgen deprivation therapy for prostate cancer.
Margaret E. Long(University of Iowa Hospitals and Clinics), James A. Brown(University of Iowa Health Care), Yousef Zakharia(University of Iowa), Chad R. Tracy, Andrew Vitale(University of Iowa), Rohan Garje(Baptist Hospital of Miami), Sarah L. Mott(University of Iowa)
PubMed
August 1, 2021
Cited by 3
Related Papers
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2021|411
Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma
|Journal of Surgical Oncology|2014|274
Indications for and outcome of total abdominal hysterectomy for benign disease: a prospective cohort study
|BJOG An International Journal of Obstetrics & Gynaecology|1995|215
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
|The Journal of Urology|2019|190
Substrate-Based Design of the First Class of Angiotensin-Converting Enzyme-Related Carboxypeptidase (ACE2) Inhibitors
|Journal of the American Chemical Society|2002|189